ChiCTR2600124940 版本V1.0 版本创建时间2026/05/19 15:49:20 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600124940 

最近更新日期:

Date of Last Refreshed on:

2026-05-19 15:48:38 

注册时间:

Date of Registration:

2026-05-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于 AI 智能体的肺癌术后患者医院-家庭过渡期症状管理模式构建与初步应用

Public title:

An AI Agent-Based Symptom Management Model for the Hospital-to-Home Transition of Postoperative Lung Cancer Patients: Development and Pilot Application

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于 AI 智能体的肺癌术后患者医院-家庭过渡期症状管理模式构建与初步应用

Scientific title:

An AI Agent-Based Symptom Management Model for the Hospital-to-Home Transition of Postoperative Lung Cancer Patients: Development and Pilot Application

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

沈雅洁 

研究负责人:

沈雅洁 

Applicant:

Yajie Shen 

Study leader:

Yajie Shen 

申请注册联系人电话:

Applicant telephone:

+86 20 8775 5766

研究负责人电话:

Study leader's
telephone:

+86 20 8775 5766

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

syj8731@126.com

研究负责人电子邮件:

Study leader's E-mail:

syj8731@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区中山二路58号

研究负责人通讯地址:

广州市中山二路58号

Applicant address:

58 Zhongshan Er Road, Guangzhou, Guangdong

Study leader's address:

58 Zhongshan Road 2nd, Guangzhou 510080, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第一医院

Applicant's institution:

The First Affiliated Hospital, Sun Yat-sen University

研究负责人所在单位:

中山大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital,Sun Yat-sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审临[2026]110 号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第一医院临床科研和实验动物伦理委员会

Name of the ethic committee:

IEC for Clinical Research and Animal Trials of the First Affiliated Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-06 00:00:00

伦理委员会联系人:

陈湛勇

Contact Name of the ethic committee:

Chen Zhanyong

伦理委员会联系地址:

广州市中山二路58号

Contact Address of the ethic committee:

58 Zhongshan Road 2nd, Guangzhou 510080, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 87338035

伦理委员会联系人邮箱:

Contact email of the ethic committee:

chenzhy233@mail.sysu.edu.cn

研究实施负责(组长)单位:

中山大学附属第一医院

Primary sponsor:

The First Affiliated Hospital,Sun Yat-sen University

研究实施负责(组长)单位地址:

广州市中山二路58号

Primary sponsor's address:

58 Zhongshan Road 2nd, Guangzhou 510080, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第一医院

具体地址:

广州市中山二路58号

Institution
hospital:

The First Affiliated Hospital,Sun Yat-sen University

Address:

58 Zhongshan Road 2nd, Guangzhou 510080, China

经费或物资来源:

Source(s) of funding:

None

研究疾病:

肺癌  

Target disease:

Lung Cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

构建基于AI智能体的肺癌术后患者居家症状管理模式,并与常规护理相比,评估该模式对改善肺癌术后患者出院后4周内症状负担的效果。  

Objectives of Study:

To construct a home symptom management model for postoperative lung cancer patients based on AI agents, and to evaluate the effect of using this model on improving the symptom burden of postoperative lung cancer patients within 4 weeks after discharge compared with conventional care.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18 岁; 2.病理诊断为肺癌,并在我院胸外科已完成预定肺癌根治性手术; 3.预计生存期>3 个月; 4.意识清楚,具备基本的读写能力,能熟练使用智能手机微信小程序; 5.知情同意, 自愿参加本研究并签署《知情同意书》。

Inclusion criteria

1. Aged >=18 years; 2. Pathologically diagnosed with lung cancer and have undergone scheduled curative lung cancer surgery in the thoracic surgery department of our hospital; 3. Life expectancy > 3 months; 4. Mentally competent, possessing basic reading and writing skills, and proficient in using the WeChat mini-program on a smartphone; 5. Provide informed consent, voluntarily participate in this study, and sign the informed consent form.

排除标准:

1.存在严重视力、听力或认知障碍,无法完成问卷或与 AI 交互; 2.合并其他严重器官功能障碍或精神疾病; 3.术后出现严重并发症,需长期住院或转至康复机构; 4.同期参与其他干预性研究。

Exclusion criteria:

1. Severe visual, hearing, or cognitive impairments that prevent completion of questionnaires or interaction with the AI; 2. Comorbid with other severe organ dysfunction or mental disorders; 3. Severe postoperative complications requiring prolonged hospitalization or transfer to a rehabilitation facility; 4. Concurrent participation in other interventional studies.

研究实施时间:

Study execute time:

From 2026-03-02 00:00:00 To 2028-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-02 00:00:00 To 2028-03-01 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

63

Group:

intervention group

Sample size:

干预措施:

AI智能体干预

干预措施代码:

Intervention:

AI agent intervention

Intervention code:

组别:

对照组

样本量:

63

Group:

control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

usual care

Intervention code:

组别:

访谈组

样本量:

15

Group:

Interview group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital,Sun Yat-sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

症状评分

指标类型:

主要指标

Outcome:

Symptom Score

Type:

Primary indicator

测量时间点:

出院当天、出院后1、2、3周及干预结束后3天内

测量方法:

使用中文版安德森症状评估量表进行评估。

Measure time point of outcome:

On the day of discharge, at 1, 2, and 3 weeks after discharge, and within 3 days after the intervent

Measure method:

The Chinese version of the M.D. Anderson Symptom Inventory (MDASI) was used for assessment.

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of Life

Type:

Secondary indicator

测量时间点:

出院当天、干预结束后3天内

测量方法:

使用中文版肺癌患者生活质量评估量表EORTC QLQ-LC43进行评估。

Measure time point of outcome:

On the day of discharge,and within 3 days after the intervent

Measure method:

The Chinese version of the EORTC QLQ-LC43 was used for assessment.

指标中文名:

出院后30天内非计划再入院率和急诊就诊率

指标类型:

次要指标

Outcome:

The rates of unplanned hospital readmission and emergency department visits within 30 days after discharge

Type:

Secondary indicator

测量时间点:

干预结束后3天内

测量方法:

Measure time point of outcome:

Within 3 days after the intervention

Measure method:

指标中文名:

自我效能

指标类型:

次要指标

Outcome:

patient self-management capacity

Type:

Secondary indicator

测量时间点:

出院当天、干预结束后3天内

测量方法:

使用中文版癌症自我管理效能感量表进行评估。

Measure time point of outcome:

On the day of discharge,and within 3 days after the intervent

Measure method:

The Chinese version of the Strategies Used by People to Promote Health,SUPP H was used for assessment.

指标中文名:

康复锻炼完成情况

指标类型:

次要指标

Outcome:

completion of rehabilitation exercises

Type:

Secondary indicator

测量时间点:

出院后1、2、3周及干预结束后3天内

测量方法:

Measure time point of outcome:

at 1, 2, and 3 weeks after discharge, and within 3 days after the intervent

Measure method:

指标中文名:

患者满意度

指标类型:

次要指标

Outcome:

patient satisfaction

Type:

Secondary indicator

测量时间点:

干预结束后3天内

测量方法:

使用自制满意度调查问卷,从患者对AI智能体的使用体验、满意度、开放性问题三方面进行调查。

Measure time point of outcome:

within 3 days after the intervent

Measure method:

A self-developed satisfaction questionnaire was used to survey patients across three domains: user experience with the AI agent, overall satisfaction, and open-ended questions.

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

postoperative complications

Type:

Secondary indicator

测量时间点:

干预结束后3天内

测量方法:

Measure time point of outcome:

Within 3 days after the intervention

Measure method:

指标中文名:

肺功能

指标类型:

主要指标

Outcome:

pulmonary function

Type:

Primary indicator

测量时间点:

术前及干预结束后3天内

测量方法:

采用便携式肺功能检测仪测定

Measure time point of outcome:

Preoperatively and within 3 days after the intervention.

Measure method:

using a portable spirometer

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not share

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究将采用符合 21 CFR Part 11 标准的电子数据采集(EDC)系统进行所有数据的收集与管理。数据收集计划涵盖基线资料、临床特征及量表评分(于研究中心录入),主要/次要疗效终点(通过电子问卷直接采集以保持客观性),医疗资源利用数据(电话随访后录入)以及系统自动记录的过程指标和安全性事件。该 EDC 系统通过内置逻辑核查(如范围检查、逻辑校验)、完整的稽查轨迹、严格的权限控制和闭环的质疑管理功能,从源头确保数据的准确性与可靠性,同时系统的高可用性和自动备份机制保证了数据存储的安全与稳定。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study will adopt an electronic data capture (EDC) system compliant with 21 CFR Part 11 standards for collecting and managing all data. The data collection plan covers baseline data, clinical characteristics, and scale scores (entered at the study center), primary/secondary efficacy endpoints (directly collected via electronic questionnaires to ensure objectivity), medical resource utilization data (entered after telephone follow-up), as well as process indicators and safety events automatically recorded by the system. Through built-in logical checks (e.g., range checks and logical verification), complete audit trails, strict access control, and a closed-loop query management function, the EDC system ensures the accuracy and reliability of data from the source. Meanwhile, the system’s high availability and automatic backup mechanism guarantee the security and stability of data storage.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-05-19 15:48:38